Genomes and Genes
Summary: Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Publications224 found, 100 shown here
- Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantationD Sangiolo
Institute for Cancer Research and Treatment IRCC, Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo TO, Italy
Expert Opin Biol Ther 9:831-40. 2009..The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful...
- Graft-versus-leukemia effects of transplantation and donor lymphocytesHans Jochem Kolb
Department of Medicine 3, Hematopoietic Cell Transplantation, University of Munich and Helmholtz Zentrum Muenchen National Research Centre for Environmental Health, Munich, Germany
Blood 112:4371-83. 2008..Recently, we have learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for ..
- Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanomaAndreas Mackensen
Department of Hematology Oncology, University of Regensburg, Franz Josef Strauss Allee 11, D 93042 Regensburg, Germany
J Clin Oncol 24:5060-9. 2006..A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients...
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
Science 298:850-4. 2002..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
- Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cellsJingting Jiang
The Third Affiliated Hospital, Suzhou University, Changzhou 213003, China
Anticancer Res 26:2237-42. 2006..It is concluded that chemotherapy plus CIK cells has obvious benefits for patients who suffer from advanced gastric cancers...
- Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanomaEduardo Huarte
Department of Medicine, Lebanon, NH 03756, USA
Cancer Lett 285:80-8. 2009....
- Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trialKoji Kono
First Department of Surgery, Yamanashi Medical University, 1110 Tamaho, Yamanashi 409 3898, Japan
Clin Cancer Res 8:1767-71. 2002We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved ..
- Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumorMichael S Sabel
University of Michigan, Department of Surgery, Division of Surgical Oncology, 3304 Cancer Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
Cryobiology 53:360-6. 2006..We examined whether cryoablated tumor draining lymph nodes (CTDLN) as adoptive immunotherapy may be an effective immunotherapeutic approach in the adjuvant treatment of breast cancer...
- Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseCatherine M Bollard
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
J Exp Med 200:1623-33. 2004..clearly identified tumor antigens derived from the virus and could, in principle, be a target for adoptive immunotherapy with viral antigen-specific T cells...
- Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancerChangping Wu
The Third Affiliated Hospital of Suzhou University, Changzhou 213003, PR China
Anticancer Res 28:3997-4002. 2008..It was concluded that chemotherapy plus CIK cells has potential benefits compared to chemotherapy alone in patients suffering from advanced NSCLC and autologous CIK cell transfusion has no obvious side-effects...
- Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cellsL J Berry
Cancer Immunology Program, Peter MacCallum Cancer Centre, Victoria, Australia
Tissue Antigens 74:277-89. 2009..This review discusses the latest developments in the field of adoptive immunotherapy using genetically modified immune cells that have been transduced with either TCR or scFv receptor ..
- Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cellsMathias Oelke
Department of Pathology and Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Nat Med 9:619-24. 2003b>Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T ..
- Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectorsSara Bobisse
Department of Oncology, University of Padova, Padova, Italy
Cancer Res 69:9385-94. 2009..Overall, our results indicate that lentiviral vectors represent a valid tool for stable and high-intensity expression of transgenic TCR and support clinical exploitation of this approach for therapeutic application...
- Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacityChy Anh Tran
Division of Hematology Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
J Immunother 30:644-54. 2007..of patient-specific cell products to produce large numbers of T-lymphocytes in support of phase 2 adoptive immunotherapy trials for hematologic malignancies...
- Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitopeMalcolm S Mitchell
Center for Biological Therapy and Melanoma Research, University of California San Diego School of Medicine, San Diego, CA, USA
J Clin Oncol 20:1075-86. 2002..To study distribution and toxicity of cytolytic T lymphocytes (CTLs) against a single melanoma epitope...
- Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipientsB Savoldo
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Transplantation 72:1078-86. 2001..b>Adoptive immunotherapy may have therapeutic potential in this setting, but there is little experience in generating autologous ..
- Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseasesS Sakaguchi
Precursory Research for Embryonic Science and Technology PRESTO, Research and Development Corporation of Japan JRDC, Tsukuba Life Science Center
J Immunol 155:1151-64. 1995..Abnormality of this T cell-mediated mechanism of peripheral tolerance can be a possible cause of various autoimmune diseases...
- Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapyJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother (1997) 28:53-62. 2005The authors recently reported that adoptive immunotherapy with autologous tumor-reactive tumor infiltrating lymphocytes (TILs) immediately following a conditioning nonmyeloablative chemotherapy regimen resulted in an enhanced clinical ..
- Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantationKatia Perruccio
Department of Clinical and Experimental Medicine, IRCCS Foundation on Transplantation Biotechnologies, University of Perugia, Via Brunamonti 51, 06123, Italy
Blood Cells Mol Dis 40:76-83. 2008..Consequently, a clinical trial is planned to incorporate infusion of photo-allodepleted donor T cells after haploidentical stem cell transplantation with the aim of decreasing infection-related mortality...
- Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemiaJ K Orleans-Lindsay
Department of Haematology, Royal Free University College Medical School, London, UK
Clin Exp Immunol 126:403-11. 2001Evidence of an immune mediated graft-versus-leukaemia effect has led to the belief that T and NK cell based adoptive immunotherapy can constitute effective treatment for relapsed leukaemias...
- CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapyK A Ward
Bone Marrow Transplant Programme, Alfred Hospital, Melbourne, Australia
Cytotherapy 8:130-40. 2006..However, significant heterogeneity within DC preparations is apparent and supports the existence of several distinct DC subpopulations. This study aimed to expand and characterize CD34+ DC for use in immunotherapy...
- In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naÃ¯ve repertoireWilliam Y Ho
Program in Immunology, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA 98109, USA
J Immunol Methods 310:40-52. 2006..on in vivo vaccination trials, but also to generate T-cell lines or clones that could be used directly for adoptive immunotherapy approaches...
- Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell linesKarl S Peggs
Royal Free and University College London Medical School, London, UK
Lancet 362:1375-7. 2003..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
- Adoptive immunotherapy of HCMV infectionM Kapp
Medizinische Klinik und Poliklinik II, Julius Maximilians University of Wurzburg, Germany
Cytotherapy 9:699-711. 2007..In this review, we aim to provide a comprehensive synopsis of the current standard of knowledge concerning cellular HCMV-specific immunotherapeutic approaches...
- Next generation adoptive immunotherapy--human T cells as carriers of therapeutic nanoparticlesM W Mortensen
Nano Science Center, University of Copenhagen, Universitetsparken 5, DK 2100 Copenhagen, Denmark
J Nanosci Nanotechnol 7:4575-80. 2007An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site...
- CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cellsPaul A Antony
Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 174:2591-601. 2005..Paradoxically, we found that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cells directed against a persisting tumor/self-Ag...
- Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patientsViviana P Lutzky
EBV Biology Laboratory, Division of Immunology, Australian Centre for Vaccine Development, The Queensland Institute of Medical Research, The Royal Brisbane Hospital, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
Immunol Cell Biol 87:481-8. 2009..In order to maximize the expansion of LMP-specific CTL in vitro for use in adoptive immunotherapy of nasopharyngeal carcinoma patients, we used lymphoblastoid cell lines coated with synthetic peptides ..
- Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigenRosalind Polley
Immunology and Infection Unit, Dept. of Biology, University of York, P.O. Box 373, York YO10 5YW, United Kingdom
Infect Immun 74:773-6. 2006..Here, we demonstrate that successful adoptive immunotherapy with CD8+ T cells is strictly dependent upon the presence of cognate antigen.
- Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancerAnnemieke de Jong
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Building 1 E3-Q, 2300 RC Leiden, The Netherlands
Int J Cancer 114:274-82. 2005..These HPV16E6-specific CD4(+) T cells may turn out to be an essential component of future adoptive T cell therapy for advanced cervical cancer, by orchestrating CTL dependent and independent tumoricidal mechanisms...
- Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imagingMatthias Edinger
Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA, USA
Blood 101:640-8. 2003..The complex cellular processes in bone marrow transplantation and antitumor immunotherapy, previously inaccessible to investigation, can now be revealed in real time in living animals...
- Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signalingRajani Ravi
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
Cancer Res 66:1730-9. 2006....
- Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1Toru Kawaoka
Department of Digestive Surgery and Surgical Oncology Department of Surgery II, Yamaguchi University Graduate School of Medicine, Yamaguchi 755 8505, Japan
Oncol Rep 20:155-63. 2008..In this study, we performed adoptive immunotherapy (AIT) in patients with PC with CTLs stimulated by the MUC1-expressing human PC cell line YPK-1...
- Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approachPouneh Dokouhaki
Toronto General Research Institute, University Health Network, Toronto, Canada
Cancer Lett 297:126-36. 2010gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently...
- Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancerMona Karlsson
Karolinska Institute, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Ann Surg Oncol 17:1747-57. 2010..We have conducted a pilot study of a novel adoptive immunotherapy, using autologous, in vitro expanded lymphocytes isolated from the tumor-draining sentinel lymph node.
- Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot studyHirohito Kobayashi
Department of Urology, Tokyo Women s Medical University, 8 1 Kawada cho, Shinjuku ku, Tokyo 162 8666, Japan
Cancer Immunol Immunother 56:469-76. 2007..have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried...
- Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerRajeev K Shrimali
Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
Cancer Res 70:6171-80. 2010..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
- Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytesKarin C M Straathof
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
Blood 105:1898-904. 2005..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
- Natural-killer-cell-based treatment in haematopoietic stem-cell transplantationJakob R Passweg
Service d Hematologie, Departement Medecine Interne, Hopitaux Universitaires de Geneve, Geneve, Switzerland
Best Pract Res Clin Haematol 19:811-24. 2006b>Adoptive immunotherapy using natural killer (NK) cells is currently under investigation, especially in situations where anti-neoplastic effect is needed but infusion of T cells is considered hazardous, such as in recipients of ..
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G Till
Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 112:2261-71. 2008b>Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects...
- NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivoTadepally Lakshmikanth
Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Italy
J Clin Invest 119:1251-63. 2009....
- CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapyJ L Schultze
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Invest 100:2757-65. 1997..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy.
- An inducible caspase 9 safety switch for T-cell therapyKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Meidcine, Houston, TX 77030, USA
Blood 105:4247-54. 2005..Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies...
- Adoptive immunotherapy of cancer using CD4(+) T cellsPawel Muranski
National Cancer Institute, NIH, Bethesda, MD 20892, USA
Curr Opin Immunol 21:200-8. 2009....
- A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMark E Dudley
Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Immunother 25:243-51. 2002..a phase I clinical trial using nonmyeloablative, lympho-depleting chemotherapy in combination with adoptive immunotherapy in patients with metastatic melanoma...
- Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferonJacques Banchereau
Baylor Institute for Immunology Research, Dallas, TX, USA
J Immunother 28:505-16. 2005..Overall, these results suggest that IFN-alpha-activated CD34-DCs are safe but elicit only limited immune responses, underscoring the need to test different DC maturation factors...
- Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanomaM E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
J Immunother 24:363-73. 2001..The lack of clinical effectiveness of this protocol suggests that transfer of different or additional cell types or that modulation of the recipient host environment is required for successful therapy...
- Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in childrenU Koehl
University Hospital Frankfurt, Pediatric Hematology and Oncology, Frankfurt, Germany
Klin Padiatr 217:345-50. 2005..For a possible benefit of post transplant treatment with NK cells after haploidentical stem cell transplantation (haplo-SCT) we developed a clinical scale procedure for NK cell processing observing Good Manufacturing Practice (GMP)...
- Capture and generation of adenovirus specific T cells for adoptive immunotherapyIlenia Chatziandreou
Molecular Immunology Unit, Institute of Child Health, University College London, London, UK
Br J Haematol 136:117-26. 2007..The protocols can be readily translated to generate ADV-specific T cells suitable for clinical use and offer an effective immunotherapeutic strategy to control ADV infection...
- Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myelomaNicolaus Kroger
Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
Blood 104:3361-3. 2004..The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus ..
- Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunityChristian S Hinrichs
National Cancer Institute, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 106:17469-74. 2009..better than those derived from effector memory populations, suggesting that they are superior for use in adoptive immunotherapy studies...
- Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapyE Goulmy
Department of Immunohematology and Blood Bank, Leiden University Hospital, The Netherlands
Immunol Rev 157:125-40. 1997..Directly relevant is the utility of mHag molecular typing for diagnostics in BM donor selection. Most promising is the use of mHag-specific cytotoxic T cells for adoptive immunotherapy of leukemia.
- The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsetsDavid A Horwitz
Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles 90033 1034, USA
J Leukoc Biol 74:471-8. 2003..Finally, the potential use of regulatory T cells generated ex vivo as an adoptive immunotherapy for certain autoimmune diseases, to prevent organ graft rejection, or to prevent pathologic host responses ..
- Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapyQiao Li
Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan 48109-0932, USA
Cancer Res 63:2546-52. 2003..of TDLN cells activated through 4-1BB in conjunction with CD3/CD28 pathways was examined using an adoptive immunotherapy model...
- Adoptive T cell therapy for cancer in the clinicCarl H June
Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Clin Invest 117:1466-76. 2007..Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein...
- A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphomaThomas Leemhuis
Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
Biol Blood Marrow Transplant 11:181-7. 2005....
- Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunityLei Shen
Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
Nat Biotechnol 22:1546-53. 2004..This study has implications for understanding the regulation of antigen presentation and for developing more effective tumor vaccines by silencing the critical brake in antigen presentation...
- CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancerMark J Smyth
Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
J Immunol 176:1582-7. 2006..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
- Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2Sameek Roychowdhury
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
Cancer Res 64:8062-7. 2004b>Adoptive immunotherapy with tumor-specific T cells has emerged as a valid approach for prevention or treatment of diseases, such as melanoma and EBV-associated lymphoma...
- Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II studyBrian I Rini
Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
Biol Blood Marrow Transplant 12:778-85. 2006..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
- Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical studyJohn K Chan
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
Clin Cancer Res 12:1859-67. 2006..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
- Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytesHiroshi Kondo
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755 8505, Japan
Anticancer Res 28:379-87. 2008..The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and, cytotoxic T lymphocyte (CTL) sensitized with a pancreatic cancer, YPK-1, expressing MUC1 (MUC1-CTL) was evaluated...
- Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BBMarcela V Maus
Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
Nat Biotechnol 20:143-8. 2002..Furthermore, apoptosis of cultured CD8(+) T cells was diminished by this approach. This approach may have important therapeutic implications for adoptive immunotherapy.
- A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinomaDaniel H Palmer
Cancer Research UK Clinical Trials Unit, CR UK Institute for Cancer Studies, Clinical Research Block
Hepatology 49:124-32. 2009..Immune responses were assessed using an ELIspot assay of interferon-gamma (IFN-gamma) release. In several cases there was induction of T cell responses to the vaccine and/or AFP following vaccination...
- Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapyD Montagna
BMT Laboratory and BMT Units, Department of Pediatrics, Laboratory of Organ Transplantation, IRCCS Policlinico San Matteo, University of Pavia, Italy
Blood 98:3359-66. 2001..does not require definition of the target antigen and because it selects responding cells from a virgin T-cell repertoire, its general application is suggested in adoptive immunotherapy and in the definition of tumor rejection antigens.
- Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cellMarcus O Butler
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 13:1857-67. 2007..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)...
- Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccineJ Banchereau
Baylor Institute for Immunology Research, Dallas, Texas 75204, USA
Cancer Res 61:6451-8. 2001..Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015)...
- Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancerK Birkholz
Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
Gene Ther 16:596-604. 2009..with a new defined specificity by expression of a chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer...
- Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunityAnna K Palucka
Baylor Institute for Immunology Research, Sammons Cancer Center, 3434 Live Oak, Dallas, TX 75204, USA
J Immunother 29:545-57. 2006..Thus, the present results justify the design of larger follow-up studies to assess the clinical response to DC vaccines loaded with killed allogeneic tumor cells in patients with metastatic melanoma...
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cellsSilke Holtkamp
Division of Experimental and Translational Oncology, Department of Internal Medicine III, Johannes Gutenberg University, Obere Zahlbacherstr. 63, 55131 Mainz, Germany
Blood 108:4009-17. 2006..In summary, our data provide a strategy for optimizing RNA-transfected DC vaccines and a basis for defining release criteria for such vaccine preparations...
- [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis]Jian Ping Pan
Institute of Immunology, Zhejiang University, Hangzhou 310031, China
Zhonghua Zhong Liu Za Zhi 28:646-9. 2006..To investigate the anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell (DC-sVEGFR-2) vaccination...
- Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responsesLaurence Chapatte
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland
Cancer Res 66:5461-8. 2006..These results suggest that the inefficient processing of self-antigens, such as Melan-A, by the immunoproteasomes of professional antigen-presenting cells prevents the induction of antitumor T-cell responses in vivo...
- Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cellsShigeo Koido
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Vaccine 25:2610-9. 2007..Such fusion cells hold promise since they can be used as a vaccine for active immunotherapy or as stimulators to activate and expand T cells for adoptive immunotherapy.
- Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunityT Tatsumi
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan
Gene Ther 14:863-71. 2007..These results revealed that IL-12 gene transfer is capable of improving the impaired functions of DC isolated from tumor-bearing hosts, and support the preclinical therapeutic efficacy of intrahepatic injection of AdIL12DC...
- Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigenAsim Saha
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH45267, USA
Immunology 118:483-96. 2006..The adoptive transfer experiments also suggested the role of both CD4+ and CD8+ T cells in this model system. Furthermore, mice that had rejected C15 tumour growth, developed tumour-specific immunological memory...
- Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cellsMai Tomiyama
Yokohama City University, School of Medicine, 3-9 Fukura, Kanazawa-ku, Yokohama, Japan
Anticancer Res 24:3327-33. 2004..findings that mDCs can efficiently expand antigen-specific naive and memory CD8 + T cells have important implications in the development of vaccination strategies and support the use of antigen-loaded mature DCs in human clinical trials..
- Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunityTianpei He
Research Unit, Health Research Division, Saskatchewan Cancer Agency, Department of Oncology, University of Saskatchewan, Saskatoon, Saskatchewan S7N 4H4, Canada
Cell Mol Immunol 4:105-11. 2007..Therefore, IFN-gamma-activated immortal DC2.4 cells may prove to be useful in the study of DC biology and antitumor immunity...
- A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrenceYunping Luo
Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA
Cancer Res 65:3419-27. 2005....
- Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cellsH J Bontkes
Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Gene Ther 14:366-75. 2007..These transfected mature DC migrated efficiently towards lymph node derived chemokines. DCs constitutively expressing IL-12p70, generate TAA-specific cytotoxic T cells with an high functional avidity, independent of CD4+ T-cell help...
- Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cellsSheng Wu
Institute of Molecular Medicine and State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, PR China
Int J Oncol 28:731-6. 2006..These findings provided the first evidence that immunization with a low dose of unmodified live FO cells was safe to mice and capable of eliciting specific protective immunity against tumor growth...
- The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunityRobert M Prins
Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
J Immunol 176:157-64. 2006..Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod...
- The maturation of murine bone marrow-derived dendritic cells by tumor lysate uptake in vitro is not essential for cancer immunotherapySung-Chil Woo
Department of Microbiology and Immunology, National Research Laboratory of Dendritic Cell Differentiation and Regulation, Medical Research Institute, Busan, Korea
Cancer Biol Ther 4:1331-5. 2005..These results demonstrate that augmentation of DC phenotype and function in vitro is not necessarily a prerequisite for TP-DC vaccination to successfully promote anti-tumor immunity in vivo...
- Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigenAsim Saha
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0509, USA
Cancer Res 67:2881-92. 2007..These results suggest the potential use of this vaccination strategy for future clinical applications...
- Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune controlFabrizio Vianello
Partners AIDS Research Center, Infectious Diseases Division, and Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA
J Immunol 176:2902-14. 2006..The repulsion of tumor Ag-specific T cells away from melanomas expressing CXCL12 confirms the chemorepellent activity of high concentrations of CXCL12 and may represent a novel mechanism by which certain tumors evade the immune system...
- Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in miceHidetsugu Asada
Department of Biotechnology, Faculty of Engineering, Kyoto Sangyo University, Kyoto 603-8555, Japan
Cancer Lett 240:83-93. 2006..Compared with the CD8(+) cells, the CD4(+)T cells more remarkably improved the efficacy of DC-based immunotherapy. The present system may be a feasible therapeutic modality to eradicate malignancies including melanoma...
- Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccinesRichard C Koya
Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Mol Ther 15:971-80. 2007..Thus, DC precursors can be genetically engineered after a single ex vivo manipulation, resulting in DC vaccines with improved activity...
- Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regressionC L Fong
Division of Cellular and Molecular Research, National Cancer Centre, Singapore
Gene Ther 13:245-56. 2006..However, systemic expansion of DC prior to immunization did not enhance the specific cellular response, suggesting that it is in situ recruitment or expansion of DC that is critical for pNGVL-hFLex-MUC-1 potency...
- The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigenToshiyasu Ojima
Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama 641-8510, Japan
Int J Oncol 28:947-53. 2006....
- A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cellsRajkumar Savai
Department of Hematology, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
Cancer Res 67:5443-53. 2007..Our findings indicate that the combination therapy of dendritic cell-tumor cell HC-Vacc/ACT is a very effective and a promising immunotherapeutic regimen against poorly immunogenic carcinomas...
- Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccineYanfeng Wu
Institute of Immunology, Second Military Medical University, Shanghai, People's Republic of China
Cancer Res 65:4947-54. 2005..Therefore, Hsp70L1 has potent adjuvant effect in form of fusion protein, indicating that Hsp70L1 may be widely used as Th1 adjuvant to prepare antigenic fusion protein for the therapeutics of cancer or infectious diseases...
- Antigenic targets for renal cell carcinoma immunotherapyJohannes Vieweg
Duke University Medical Center, MSRB, Suite 455, PO Box 2626, Durham, North Carolina 27710, USA
Expert Opin Biol Ther 4:1791-801. 2004..Continued identification of molecular targets, in concert with more effective vaccination protocols, is likely to produce vaccination strategies with clinical impact...
- A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responsesZ You
Center for Cell and Gene Therapy, and Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Res 61:197-205. 2001..Thus, this retrogen strategy of using a unifying mechanism for DCs to cross-present an intracellular tumor antigen in a cognate manner could be generally used to improve the efficacy of tumor vaccines and immunotherapies...
- Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinomaElzbieta Pajtasz-Piasecka
L Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Immunol Lett 116:24-32. 2008..Therefore, pretreatment of DCs with the phages may be considered as a beneficial element of a novel strategy in anti-tumor immunotherapy...
- Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protectionGeorge Miller
Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Res 62:5260-6. 2002....
- Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccinesAntoni Ribas
Department of Surgery, University of California at Los Angeles, 90095-1782, USA
Cancer Gene Ther 9:875-83. 2002..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection...
- Dendritic cell based personalized immunotherapy based on cancer antigen researchYutaka Kawakami
Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University, School of Medicine, Tokyo, Japan
Front Biosci 13:1952-8. 2008....
- Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignanciesStephen Gottschalk
Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Blood 101:1905-12. 2003..Thus, DeltaLMP1 expression in DCs is nontoxic and enables the generation of LMP1-specific CTLs for future adoptive immunotherapy protocols for patients with LMP1-positive malignancies such as EBV-positive Hodgkin disease...
- Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in miceYuji Satoh
Biologic Therapeutics Program, University of Pittsburgh Cancer Institute, 5725 CHP-MT, 200 Lothrop Street, Pittsburgh, PA 15213, USA
J Exp Ther Oncol 2:337-49. 2002..Simultaneous local gene therapy with IL-12 will further improve clinical efficacy without placing the patient at risk for systemic toxicity...
- Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivoLianhua Bai
German Cancer Research Center, Division of Cellular Immunology, Heidelberg, Germany
Int J Cancer 103:73-83. 2003..Our findings suggest that cognate interactions between cancer patient-derived memory BM-T cells and tumor antigen-presenting BM-DCs are important for reciprocal cell stimulation, survival and therapeutic activity...
- Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cellsKenichi Akiyama
Department of Experimental Immunology and Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Sendai, Japan
J Immunol 170:1641-8. 2003..These results show that using ATC-ICs may overcome the limitations and may enhance the immune response of current ATC-based DC vaccination therapy...
- Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in miceMasoumeh Khamisabadi
Department of Immunology, School of Medicine, Medical Sciences University of Tehran, Tehran, Iran
Iran J Immunol 5:36-44. 2008..It has been demonstrated that Listeria monocytogenes activated DCs pulsed ex vivo with tumor antigens trigger a systemic Th1-biased specific immune response and a single dose of this vaccine will cause a considerable anti tumor immunity...
- A dendritic cell vaccine induces protective immunity to intracranial growth of gliomaO Insug
The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
Anticancer Res 22:613-21. 2002..The efficacy of the vaccine was improved further by administration of recombinant interleukin-12 into the vaccine regimen...
- CD8+ T Cell Immunity to CytomegalovirusStanley R Riddell; Fiscal Year: 2010..by this project have investigated the immunobiology of CMV infection and developed strategies for specific adoptive immunotherapy with CD8+ T cell clones to correct deficiencies of T cell immunity that permit the progression of CMV ..
- Imaging Infused CD19 Specific T Cells in the TumorLAURENCE COOPER; Fiscal Year: 2007..Gene therapy can improve the therapeutic potential of adoptive immunotherapy and as recently published (Science 2006 Aug 31), infusion of genetically modified T cells with redirected ..
- CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCYJohn Levine; Fiscal Year: 2006..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
- Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasLinda M Liau; Fiscal Year: 2010..Toward these goals, we have actively explored permutations of local adoptive immunotherapy for human malignant gliomas with autologous and allogeneic effector cells...
- Leukocyte-Endothelial Adhesion in Tumor ImmunitySharon S Evans; Fiscal Year: 2010..molecules (adhesion receptors, chemokines) that recruit T cells in a murine B16 melanoma model of adoptive immunotherapy. Complementary in situ imaging studies will investigate the contribution of endogenous human IL-6 in ..
- SPORE in LymphomaRichard Ambinder; Fiscal Year: 2007..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
- T CELL TRAFFICKING IN ADOPTIVE CELLULAR IMMUNOTHERAPYLloyd Stoolman; Fiscal Year: 2000..Finally, the collaboration between the PI and co-PI will enhance productivity and ensure the rapid transfer of information from a pre-clinical to a clinical setting. ..
- Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus MacaquesLeslie S Kean; Fiscal Year: 2010..1) most novel therapies for BMT (including T cell costimulation blockade, T cell adhesion blockade and adoptive immunotherapy with regulatory T cells) cannot be accurately tested in either murine or canine models for aGvHD and (2) ..
- CTLA-4 Blockade in Allo Stem Cell TransplantationEdward Ball; Fiscal Year: 2005..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
- CLONAL GVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPYROBERT TRUITT; Fiscal Year: 1990..The proposed studies are a systematic approach to optimizing the GVL effect while minimizing the GVH effect of cloned CTL. In addition, they will enable us to gain significant new insights into the pathogenesis of clonal GVH reactions...
- Novel Cellular Therapies for Ph+ leukemiaRICHARD A contact VAN ETTEN; Fiscal Year: 2010..well- characterized mouse model of CML and Ph+ B-ALL to determine the efficacy and cellular mechanisms of adoptive immunotherapy with allogeneic T-lymphocytes or natural killer (NK) cells...
- Strategies to Enhance Adoptive Transfer T Cell ClonesStanley Riddell; Fiscal Year: 2009..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
- Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.MARY L contact DISIS; Fiscal Year: 2010..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
- Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.MARY DISIS; Fiscal Year: 2009..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
- LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMTDon Diamond; Fiscal Year: 2002..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
- EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIVDEBORAH LEWINSOHN; Fiscal Year: 2002..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
- Lentiviral Vectors for TCR Immunotherapy Targeted to melanomaBoro Dropulic; Fiscal Year: 2006..Lentigen's collaborator Dr. Michael Nishimura has helped pioneer adoptive immunotherapy as a potential therapeutic approach for melanoma...